BRAF and melanoma: The study cohort consisted of 19 advanced melanoma patients (11 with Stage III and 8 with Stage IV), among which 15 underwent BRAF testing, with 5 patients harboring BRAF-mutants and 10 patients showing a WT BRAF mutant status.